Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Each year, Medical Design & Outsourcing collects thousands of data points to rank and analyze the largest medical device companies in the world, including publicly traded companies and privately held ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

Personalized medicine is a therapeutic approach involving the use of an individual’s genetic and epigenetic information to tailor drug therapy or preventive care. Rare variant analyses identify ...

Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine ...

Merck's history dates back to the late 1800s ... Then, Summit Therapeutics goes after many other indications for this medicine. It could be a pipeline in a drug as it is being investigated ...